Tag: Revumenib

Home / Revumenib

Categories

Revumenib is approved by the USFDA for relapsed or refractory acute leukemia with a KMT2A translocation

 On November 15, 2024, the Food and Drug Administration sanctioned revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia characterized by a ...
revumenib

Scan the code